Probiotics and antimicrobial protein and peptide levels in preterm infants

Acta Paediatrica, International Journal of Paediatrics

Volumn 106, Issue 11, 2017, Pages 1747-1753

  Strunk, Tobias ^a,b   Hibbert, Julie ^a   Doherty, Dorota ^c   Granland, Caitlyn ^a   Trend, Stephanie ^a   Simmer, Karen ^a,b   Burgner, David ^d,e   Patole, Sanjay ^a,b   Currie, Andrew ^a,f  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MURDOCH UNIVERSITY   (Australia)

Author keywords

Antimicrobial proteins and peptides; Bifidobacterium breve; Preterm infant; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BETA DEFENSIN 1; BETA DEFENSIN 2; CATHELICIDIN; LACTOFERRIN; PHOSPHOLIPASE A2; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; ANTIMICROBIAL CATIONIC PEPTIDE; SECRETORY PHOSPHOLIPASE A2;

ADULT; ARTICLE; BIFIDOBACTERIUM BREVE; BIRTH WEIGHT; BLOOD SAMPLING; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HUMAN; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; CHEMISTRY; FECES; MALE; NEWBORN;

ANTIMICROBIAL CATIONIC PEPTIDES; BIFIDOBACTERIUM BREVE; FECES; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LACTOFERRIN; MALE; PHOSPHOLIPASES A2, SECRETORY; PROBIOTICS; PROSPECTIVE STUDIES;

EID: 85018548405     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.13826     Document Type: Article

References (30)

1. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126: 443–56.
2. Strunk T, Inder T, Wang X, Burgner D, Mallard C, Levy O. Infection-induced inflammation and cerebral injury in preterm infants. Lancet Infect Dis 2014; 14: 751–62.
3. Denkel LA, Schwab F, Garten L, Geffers C, Gastmeier P, Piening B. Protective effect of dual-strain probiotics in preterm infants. A multi-center time series analysis. PLoS ONE, 2016; 11: e0158136.
4. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2014; 4: CD005496.
5. Rao SC, Athalye-Jape GK, Deshpande GC, Simmer KN, Patole SK. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics 2016; 137: 1–16.
6. Zhang GQ, Hu HJ, Liu CY, Shakya S, Li ZY. Probiotics for preventing late-onset sepsis in preterm neonates: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016; 95: e2581.
7. Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med 2016; 22: 713–22.
8. Trend S, Strunk T, Hibbert J, Kok CH, Zhang G, Doherty DA, et al. Antimicrobial protein and peptide concentrations and activity in human breast milk consumed by preterm infants at risk of late-onset neonatal sepsis. PLoS ONE 2015; 10: e0117038.
9. Kai-Larsen Y, Gudmundsson GH, Agerberth B. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr 2014; 103: 1000–8.
10. Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, et al. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res 2003; 53: 211–6.
11. Kai-Larsen Y, Bergsson G, Gudmundsson GH, Printz G, Jornvall H, Marchini G, et al. Antimicrobial components of the neonatal gut affected upon colonization. Pediatr Res 2007; 61: 530–6.
12. Giorgetti G, Brandimarte G, Fabiocchi F, Ricci S, Flamini P, Sandri G, et al. Interactions between innate immunity, microbiota, and probiotics. J Immunol Res 2015; 2015: 501361.
13. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76–83.
14. Schlee M, Harder J, Koten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008; 151: 528–35.
15. Mondel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009; 2: 166–72.
16. Cullen TW, Schofield WB, Barry NA, Putnam EE, Rundell EA, Trent MS, et al. Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 2015; 347: 170–5.
17. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med 2015; 21: 808–14.
18. Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr 2010; 51: 542–7.
19. Campeotto F, Baldassarre M, Laforgia N, Viallon V, Kalach N, Amati L, et al. Fecal expression of human beta-defensin-2 following birth. Neonatology 2010; 98: 365–9.
20. Baldassarre M, Fanelli M, Corvaglia L, Laforgia N. Longitudinal evaluation of human beta-defensins and tumor necrosis factor-alpha in stools of preterm and term newborns. J Pediatr Gastroenterol Nutr 2011; 53: 582.
21. Richter M, Topf HG, Groschl M, Frohlich T, Tzschoppe A, Wenzl TG, et al. Influence of gestational age, cesarean section, and type of feeding on fecal human beta-defensin 2 and tumor necrosis factor-alpha. J Pediatr Gastroenterol Nutr 2010; 51: 103–5.
22. Strunk T, Doherty D, Richmond P, Simmer K, Charles A, Levy O, et al. Reduced levels of antimicrobial proteins and peptides in human cord blood plasma. Arch Dis Child Fetal Neonatal Ed 2009; 94: F230–1.
23. Olbrich P, Pavon A, Rosso ML, Molinos A, de Felipe B, Sanchez B, et al. Association of human beta-defensin-2 serum levels and sepsis in preterm neonates*. Pediatr Crit Care Med 2013; 14: 796–800.
24. Patole S, Keil AD, Chang A, Nathan E, Doherty D, Simmer K, et al. Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates–a randomised double blind placebo controlled trial. PLoS ONE 2014; 9: e89511.
25. Prosser A, Hibbert J, Strunk T, Kok CH, Simmer K, Richmond P, et al. Phagocytosis of neonatal pathogens by peripheral blood neutrophils and monocytes from newborn preterm and term infants. Pediatr Res 2013; 74: 503–10.
26. Strunk T, Doherty D, Jacques A, Simmer K, Richmond P, Kohan R, et al. Histologic chorioamnionitis is associated with reduced risk of late-onset sepsis in preterm infants. Pediatrics 2012; 129: e134–41.
27. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004; 72: 5750–8.
28. Kabeerdoss J, Devi RS, Mary RR, Prabhavathi D, Vidya R, Mechenro J, et al. Effect of yoghurt containing Bifidobacterium lactis Bb12(R) on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutr J 2011; 10: 138.
29. Faust K, Gopel W, Moser K, Temole G, Bartels M, Wieg C, et al. Differential expression of antimicrobial polypeptides in cord blood samples of preterm and term infants. Acta Paediatr 2014; 103: e143–7.
30. Fernandez L, Langa S, Martin V, Maldonado A, Jimenez E, Martin R, et al. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res 2013; 69: 1–10.